Immunogenicity and safety of a two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (ProQuad®) in infants from 9 months of age

Vaccine

Volumn 30, Issue 20, 2012, Pages 3082-3089

  Vesikari, Timo ^a   Becker, Thomas ^b   Gajdos, Vincent ^c   Fiquet, Anne ^d,e   Thomas, Stéphane ^d   Richard, Patrick ^d   Baudin, Martine ^d  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^b Université Paris Sud 11 ^*  (Germany)

^c HÔPITAL ANTOINE BÉCLÈRE   (France)

^d SANOFI PASTEUR   (France)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Combination vaccine; Immunogenicity; MMR; ProQuad; Safety; Two dose regimen; Varicella

Indexed keywords

CHICKENPOX MEASLES MUMPS RUBELLA VACCINE;

ARTICLE; CONTROLLED STUDY; CONVULSION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG SAFETY; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFANT; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MEASLES LIKE RASH; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRAL GASTROENTERITIS; WORLD HEALTH ORGANIZATION;

EID: 84859434925     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.02.062     Document Type: Article

References (23)

1. World Health Organization. Recommended Routine Immunization (updated June 9, 2010). http://www.who.int/immunization/policy/Immunization_routine_table1.pdf.
2. Pinquier D., Gagneur A., Aubert M., Brissaud O., Le Guen C.G., Hau-Rainsard I., et al. Distribution of serum measles-neutralizing antibodies according to age in women of childbearing age in France in 2005-2006: impact of routine immunization. Pediatr Infect Dis J 2007, 26:749-750.
3. Krugman S., Giles J.P., Friedman H., Stone S. Studies on immunity to measles. J Pediatr 1965, 66:471-488.
4. Leuridan E., Hens N., Hutse V., Ieven M., Aerts M., Van D.P. Early waning of maternal measles antibodies in era of measles elimination: longitudinal study. BMJ 2010, 340:c1626.
5. Heininger U., Desgrandchamps D., Schaad U.B. Seroprevalence of varicella-zoster virus IgG antibodies in Swiss children during the first 16 months of age. Vaccine 2006, 24:3258-3260.
6. Guillén J.M., Samaniego-Colmenero Mde L., Hernández-Barrera V., Gil A. Varicella paediatric hospitalizations in Spain. Epidemiol Infect 2009, 137:519-525.
7. Health Protection Agency. Rubella notifications, by Age Group, 1989-2009. [accessed 22.11.10]. http://www.hpa.org.uk/web/HPAweb%26HPAwebStandard/HPAweb_C/1195733842982.
8. Health Protection Agency. Mumps notifications, by Age Group, 1989-2009. [accessed 22.11.10]. http://www.hpa.org.uk/web/HPAweb%26HPAwebStandard/HPAweb_C/1195733844620.
9. World Medical Organization. WMA Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. [22.10.08]. Available at: . http://www.wma.net/en/30publications/10policies/b3/.
10. Miettinen O., Nurminen M. Comparative analysis of two rates. Stat Med 1985, 4:213-226.
11. Collett D. Modelling binary data 2003, Chapman & Hall/CRC Press, Boca Raton, FL, USA. 2nd ed.
12. Newcombe R.G. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998, 17:873-890.
13. Albrecht P., Ennis F.A., Saltzman E.J., Krugman S. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J Pediatr 1977, 91:715-718.
14. Black F.L., Berman L.L., Libel M., Reichelt C.A., Pinheiro F.D., Travassos da R.A., et al. Inadequate immunity to measles in children vaccinated at an early age: effect of revaccination. Bull World Health Organ 1984, 62:315-319.
15. Nagy G., Kosa S., Takatsy S., Koller M. The use of IgM tests for analysis of the causes of measles vaccine failures: experience gained in an epidemic in Hungary in 1980 and 1981. J Med Virol 1984, 13:93-103.
16. Jacobson R.M., Poland G.A. The genetic basis for measles vaccine failure. Acta Paediatr Suppl 2004, 93:43-46.
17. Silber J.L., Chan I.S., Wang W.W., Matthews H., Kuter B.J. Immunogenicity of Oka/Merck varicella vaccine in children vaccinated at 12-14 months of age versus 15-23 months of age. Pediatr Infect Dis J 2007, 26:572-576.
18. Heininger U., Seward J.F. Varicella. Lancet 2006, 368:1365-1376.
19. Pinquier D., Gagneur A., Balu L., Brissaud O., Gras Le G.C., Hau-Rainsard I., et al. Prevalence of anti-varicella-zoster virus antibodies in French infants under 15 months of age. Clin Vaccine Immunol 2009, 16:484-487.
20. Hammond O., Wang Y., Green T., Antonello J., Kuhn R., Motley C., et al. The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection. J Med Virol 2006, 78:1679-1687.
21. Sanofi Pasteur M.S.D. ProQuad summary of product characteristics 2006.
22. Kuter B.J., Brown M.L., Hartzel J., Williams W.R., EvesiKaren A., Black S., et al. Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad). Hum Vaccine 2006, 2:205-214.
23. Jacobsen S.J., Ackerson B.K., Sy L.S., Tran T.N., Jones T.L., Yao J.F., et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine 2009, 27:4656-4661.